AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] --
AAC Accepts, published online ahead of print on 16 June 2008
This Article
Right arrow Full Text (PDF)
Right arrow Supplemental material
Right arrow Other Versions of this Article:
AAC.01677-07v1
52/9/3135    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Bethel, C. R.
Right arrow Articles by Bonomo, R. A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bethel, C. R.
Right arrow Articles by Bonomo, R. A.

 Previous Article  |  Next Article 

Antimicrob. Agents Chemother. doi:10.1128/AAC.01677-07
Copyright (c) 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Inhibition of OXA-1 {beta}-Lactamase by Penems

Christopher R. Bethel, Anne M. Distler, Mark W. Ruszczycky, Marianne P. Carey, Paul R. Carey, Andrea M. Hujer, Magda Taracila, Marion S. Helfand, Jodi M. Thomson, Matthew Kalp, Vernon E. Anderson, David A. Leonard, Kristine M. Hujer, Takao Abe, Aranapakam M. Venkatesan, Tarek S. Mansour, and Robert A. Bonomo*

Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH; Departments of Pharmacology, and Biochemistry, Case Western Reserve University School of Medicine, Cleveland, OH; Grand Valley State College, Grand Valley, MI; Wyeth Research, Chemical and Screening Sciences, Pearl River, NY

* To whom correspondence should be addressed. Email: robert.bonomo{at}med.va.gov.


   Abstract

Partnering a {beta}-lactam with a {beta}-lactamase inhibitor is a highly effective strategy to combat bacterial resistance to {beta}-lactam antibiotics mediated by serine {beta}-lactamases (E.C.3.2.5.6). To this end, we tested 2 novel penem inhibitors against OXA-1, a class D {beta}-lactamase that is resistant to inactivation by tazobactam. The Ki of each penem inhibitor for OXA-1 was in the nM range (Ki penem 1, 45 ± 8 nM; Ki penem 2, 12 ± 2 nM). The kinact of penems 1 and 2 for OXA-1 {beta}-lactamase were 0.13 ± 0.01 s-1 and 0.11 ± 0.01 s-1, respectively. Using an Inhibitor (I) to Enzyme (E) ratio of 1:1, 100 % inactivation was achieved in ≤ 900 s and OXA-1 {beta}-lactamase activity recovery was not detected at 24 h. Covalent adducts of penems 1 and 2 ({Delta} +306 ± 3 and {Delta} +321 ± 3 Da, respectively) were identified by electrospray ionization mass spectrometry (ESI-MS). After tryptic digestion of OXA-1 inactivated by penems 1 and 2, ESI-MS and matrix-assisted laser desorption/ionization (MALDI) time of flight (TOF) identified 306 ± 3 and 321 ± 3 Da adducts attached to the peptide containing the active site Ser67. Base hydrolysis of penem 2 monitored by serial 1H NMR suggested that penem 2 formed a linear imine species that underwent 7-endo-trig cyclization to ultimately form a cyclic enamine, the 1,4-thiazepine derivative. Susceptibility testing demonstrated that the penem inhibitors at 4 mg/L effectively restored piperacillin susceptibility. Penem {beta}-lactamase inhibitors which demonstrate high affinity and form long-lived acyl intermediates may prove to be extremely useful against the broad range of inhibitor-resistant serine {beta}-lactamases present in Gram-negative bacteria.







Home Help [Feedback] [For Subscribers] [Archive] [Search] --
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2008 by the American Society for Microbiology. All rights reserved.